FDA Approves Immunotherapy Duo for Kidney CancerCuretoday.comThe Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal c… Continue reading
CRISPRdisco IDs, Annotates CRISPR Repeats, Cas Genes; Assembles Data in One RepositoryGenomeWebIndeed, barely a month ago, early-stage life sciences company Arbor Biotechnologies and the team of Patrick Hsu at the Salk Institute for Biological Studies … Continue reading
CRISPRdisco IDs, Annotates CRISPR Repeats, Cas Genes; Assembles Data in One RepositoryGenomeWebIndeed, barely a month ago, early-stage life sciences company Arbor Biotechnologies and the team of Patrick Hsu at the Salk Institute for Biological Studies … Continue reading
FierceBiotech |
News of Note—New data for Fate’s off-the-shelf CAR–T in ALL; Nektar tests BMS-partnered drug in immuno-oncology …
FierceBiotech Novartis’s FDA-approved CAR–T treatment for acute lymphoblastic leukemia (ALL), Kymriah, is personalized to individual patients and targets the surface antigen CD19. Fate Therapeutics has been working on an alternative to Kymriah that the company hopes … |